Industries, Inc. has initiated a clinical trial in Europe for RAPROS®, an oral treatment designed for feline chronic kidney disease (CKD). Feline CKD is a condition that progressively impairs kidney function, often leading to symptoms such as appetite and weight loss. Left untreated, the risk of mortality significantly increases. For years, existing treatments have been inadequate in addressing this issue.
In a significant development, Toray received approval in 2017 to manufacture and market RAPROS® in Japan for the treatment of feline CKD, with Kyoritsu Seiyaku Corporation handling distribution. This approval marked a milestone, as RAPROS® became the first veterinary drug authorized to slow down the decline of kidney function in cats. By the fiscal year ending in March 2023, RAPROS® had captured approximately 70% of Japan’s market for veterinary medicinal products used in the treatment of feline CKD by value, demonstrating its effectiveness and acceptance in the market. During the fiscal years from 2017 to 2022, the compound annual growth rate (CAGR) for RAPROS® shipments was estimated at an impressive 20%.
The ongoing clinical trial in Europe aims to support an application for marketing authorization. This randomized, placebo-controlled trial involves 300 cats with CKD and will evaluate the safety and efficacy of RAPROS®. Toray initiated the trial after consulting with the Committee for Veterinary Medicinal Products (CVMP) of the European Medicines Agency (EMA) for Scientific Advice on the study design, and securing approval from European countries to conduct the trial. The company targets completion of the trial and submission of the marketing authorization application in Europe by the end of 2026. Simultaneously, Toray plans to pursue RAPROS®’ development in other key regions, including the USA and China.
Toray remains committed to advancing veterinary medicine by delivering innovative treatments that benefit pets and their owners worldwide.
